Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Abingdon Health to launch two Boots-branded self-tests

(Sharecast News) - Lateral flow test specialist Abingdon Health announced a partnership with Crest Medical on Wednesday, to introduce Boots' own-brand rapid self-tests across the UK and online. The AIM-traded firm said the initial launch would include two products, iron and vitamin D deficiency self-tests, under the Boots own-brand range.

Abingdon sid the tests were scheduled for availability in stores and online at Boots.com from the spring.

"We are delighted to announce the launch of the Boots own-brand iron and vitamin D deficiency self-tests in conjunction with our partner Crest Medical," said chief executive officer Chris Yates.

"As lateral flow experts we're proud to offer a comprehensive private label service to retailers covering a broad range of self-tests, including innovative exclusive products from Abingdon's CDMO customers.

"We take immense pride in the quality of our service and ensure a seamless supply of innovative lateral flow self-tests to ensure our partners requirements are met."

At 1041 GMT, shares in Abingdon Health were up 17.65% at 10p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.